logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Building on another blockbuster year in specialty pharmacy and generics, Rohit Vanjani, a senior analyst at Oppenheimer & Co., has reason to be excited for 2015. Vanjani specializes in nurturing firms developing novel ways to treat some of humanity's most persistent medical problems, and in this interview with The Life…
Read more...
In the healthcare space, 2014 was the year of hepatitis C. April saw the biotechnology industry take heavy losses as investors began to view stocks as overvalued following strong performance throughout 2013. But the launch of hepatitis C cure, Harvoni, by Gilead Sciences (GILD) seemed to force the realization that…
Read more...
Life sciences analyst Daniel Pearlstein of Toronto-based M Partners brings knowledge of the biotech sector and hands-on experience in the startup realm to understanding value and growth in small- and micro-cap life sciences companies. In this interview with The Life Sciences Report, Pearlstein offers his perspectives on six Canadian biotech…
Read more...
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early 2014 before rebounding, essentially following the upward trend…
Read more...
Juno Therapeutics (JUNO) JUNO is building a fully-integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. It is based in Seattle, WA. Price range mid-point increased to $22. No change in conclusion. Four other companies are scheduled for the week of Dec. 15,…
Read more...
Medovex (MDVXU) intends to build a portfolio of medical device products in areas where its world-class management team believes the largest, most targetable market opportunities exist.  It is based in Atlanta, GA. Four other companies are scheduled for the week of Dec. 15, 2014. The full IPO calendar is available…
Read more...
Bellicum Pharmaceuticals (BLCM) is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. It is based in Houston, TX. Three other companies are scheduled for the week…
Read more...
Over the holidays, I found myself commiserating with my father about the fact that no one warns you that the human body starts to break down around age 45. We don’t bounce back from an injury like we used to, and those small, irritating pains become “conditions” that must be…
Read more...
Histogenics (HSGX) is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. It is headquartered in Waltham, MA. No other companies are scheduled for the week of Dec. 1, 2014. The full IPO calendar is available at IPOpremium. Manager, Joint-managers: Cowen and…
Read more...
Being temporarily burned by the U.S. Food and Drug Administration can be a mixed blessing for a biotech with a good product in the pipeline. In an interview with The Life Sciences Report, Chen Lin, publisher of the investor newsletter What is Chen Buying? What is Chen Selling?, explains how…
Read more...
Micro-cap stocks suffer from all sorts of ills. They are often illiquid, and companies can be unable to raise new funds under reasonable terms, if at all. Investing in these equities requires extraordinary expertise and experience, and that is where micro-cap investment banker Richard "Dick" Huebner excels. In this interview…
Read more...
With delicious aromas wafting from the kitchen and holiday cheer all around, there’s nothing better than spending Thanksgiving at home among loved ones. However, if you’re stranded at an airport or stuck in traffic on your way home, it’s easy to become a Thanksgiving Grinch. Fortunately, even if you’re far…
Read more...
Page 1 of 48

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.